Nanotechnology in Prostate Cancer: PSMA-Targeted Nanoplatforms, TME-Responsive Therapy, Immunomodulation, and Clinical Translation Challenges
International Journal of Nanomedicine · 2026
DOI: 10.2147/ijn.s629751 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Nanomedicine, 2026. Verfasst von Wenjian Li. Beteiligte Einrichtung: Department of Urology, The Affiliated Changzhou Hospital of Xuzhou Medical University, Changzhou Third People's Hospital, Changzhou, Jiangsu, People'…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Antigens, Surface, Glutamate Carboxypeptidase II. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The Affiliated Changzhou Hospital of Xuzhou Medical University, Changzhou Third People's Hospital, Changzhou, Jiangsu, People's Republic of China.
ORCID-Profile: Wenjian Li
Zitieren
APA
Li, W. (2026). Nanotechnology in Prostate Cancer: PSMA-Targeted Nanoplatforms, TME-Responsive Therapy, Immunomodulation, and Clinical Translation Challenges. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s629751
Vancouver
Li W. Nanotechnology in Prostate Cancer: PSMA-Targeted Nanoplatforms, TME-Responsive Therapy, Immunomodulation, and Clinical Translation Challenges. International Journal of Nanomedicine. 2026. doi:10.2147/ijn.s629751
BibTeX
@article{Li2026,
author = {Li, Wenjian},
title = {Nanotechnology in Prostate Cancer: PSMA-Targeted Nanoplatforms, TME-Responsive Therapy, Immunomodulation, and Clinical Translation Challenges},
journal = {International Journal of Nanomedicine},
year = {2026},
doi = {10.2147/ijn.s629751}
}
EUVIMED